Edwards Lifesciences Corp (EW) has recently shown both strong and underperforming trends in the stock market. The institution is principally owned by institutional shareholders who, at one point, constituted 84% of the company's ownership. Recent developments suggest a very active period for EW, with CEO selling $750k in company stock, and purchase of 1698 share by Gryphon Financial Partners. Strong long-term growth prospects for Transcatheter Aortic Valve Replacement (TAVR), a breakthrough product offered by EW, have been identified. However, EW stocks shed 9.7% this week as yearly returns fall in accordance with earnings growth. The company released its Q4 and full-year results, showing robust performance, and has been covered by renowned firms like Goldman Sachs with a 'Buy' recommendation. Their projected strategic analysis shows a possibility of EW spinning off its critical care unit in 2024. Interestingly, investors have seen a respectable return of 50% on EW over the last five years. However, valuation adjustments in earnings spurred a trend of buying stocks during a dip.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sun, 02 Jun 2024 20:06:07 GMT -
Rating 8
- Innovation -7
- Information 9
- Rumor 4
